Form 4: BioCardia CEO Peter Altman Increases Stake in Company

BioCardia, Inc. President and CEO Peter Altman purchased 5,700 shares of common stock at a weighted average price of $0.92.

Summary

• Peter Altman, President and CEO of BioCardia, Inc., acquired 5,700 shares of common stock.
• The purchase was executed on May 18, 2026.
• The shares were acquired at a weighted average price of $0.92 per share, with individual trades ranging from $0.89 to $1.02.
• Following this transaction, the reporting person's total beneficial ownership stands at 291,566 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates the CEO is willing to deploy personal capital to increase his stake in the company.

Positives

• Insider confidence is demonstrated by the CEO increasing his equity stake in the company.
• The purchase reflects management's alignment with shareholder interests.

Negatives

• None identified in this filing.

Risks

• Market volatility affecting the share price of small-cap biotechnology companies.

Future Outlook

Not applicable as this is a disclosure of a past transaction.

Industry Context

StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed as a positive signal of management's belief in the company's clinical pipeline and long-term valuation.

Comparison to Industry Standards

• Insider purchases by CEOs are generally viewed as a standard positive signal of confidence in small-cap biotech firms.
• The transaction size is relatively small, which is common for periodic open-market accumulation by executives.

Stakeholder Impact

• Shareholders may interpret this as a sign of management confidence in the company's future prospects.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Recommendation

While insider buying is a positive signal, a single small-scale purchase by an executive does not fundamentally alter the investment thesis for a biotechnology company without further clinical or financial catalysts.

Keywords

BioCardia, BCDA, Insider Trading, Form 4, Biotechnology, Equity Ownership